At the EBMT 2025 Annual Meeting, Dr. Juan Montoro Gómez (La Fe University and Polytechnic Hospital, Valencia) presented key findings from a comparative study led by the SAAWP of the EBMT, focused on donor type and outcomes following post-transplant cyclophosphamide (PTCy) in severe aplastic anemia (SAA).
His analysis showed that while PTCy effectively mitigates both acute and chronic GVHD across donor types, matched sibling donors (MSDs) remain the gold standard due to better survival outcomes and lower non-relapse mortality. Haploidentical transplants were associated with increased NRM and inferior overall outcomes, though unrelated donors (UDs) may serve as a preferable alternative in certain cases.
Dr. Montoro emphasized the urgent need for prospective, controlled studies to further refine donor selection strategies and improve post-transplant outcomes in this fragile population.
A valuable contribution to the evolving field of transplantation in non-malignant hematologic disorders.
